Roche’s Immuno-Oncology Arsenal: PD-L1 And Beyond
This article was originally published in PharmAsia News
Executive Summary
Roche may be playing catch-up to Bristol-Myers Squibb and Merck & Co in the PD-1/PD-L1 checkpoint development space, but it believes its unique in-house strengths in diagnostics and molecular biology, coupled with partnering, will enable it to play a major role in immuno-oncology.